Shanghai Labway Clinical Laboratory Co Ltd (301060)

Shenzhen

Currency in CNY

10.98

+0.21(+1.95%)

Closed·08:44:59

Fair Value

Unlock Value

Day's Range

10.65

11.23

52 wk Range

7.55

13.26

301060 Income Statement

Featured here, the Income Statement (earnings report) for Shanghai Labway Clinical Laboratory Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2022

01/01

2023

01/01

2023

31/12

2024

31/12

Total Revenues

aa.aa

1,238.19

1,778.33

4,199.31

1,674.37

1,742.18

Total Revenues Growth

aa.aa

+7.34%

+43.62%

+136.14%

-60.13%

+4.05%

Cost Of Revenues

aa.aa

842.97

1,105.44

2,419.99

1,345.05

1,409.65

Gross Profit

aa.aa

395.22

672.9

1,779.32

329.31

332.53

Gross Profit Growth

aa.aa

+14.06%

+70.26%

+164.43%

-81.49%

+0.98%

Gross Profit Margin %

aa.aa

31.92%

37.84%

42.37%

19.67%

19.09%

Other Operating Expenses, Total

aa.aa

237.04

378.75

708.33

484.87

394.89

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+2.36%	+59.78%	+87.02%	-31.55%	-18.56%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	21.8	39.44	109.4	48.86	59.97
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	210.69	334.37	595.43	432.73	329.91
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4.55	4.93	3.5	3.27	5.01

Operating Income

aa.aa

158.18

294.15

1,070.98

-155.55

-62.37

Operating Income Growth

aa.aa

+37.63%

+85.96%

+264.1%

-114.52%

+59.91%

EBIT Margin %

aa.aa

12.78%

16.54%

25.5%

-9.29%

-3.58%

Net Interest Expenses

aa.aa

8.15

5.66

-4.93

-2.59

-0.18

Net Interest Expenses Growth

aa.aa

-1.93%

-30.47%

-187.04%

+47.49%

+92.92%

Interest Expense, Total

aa.aa

-3.27

-8.46

-8.17

-10.81

Interest And Investment Income

aa.aa

8.15

8.93

3.53

5.58

10.63

Other Non Operating Expenses, Total

aa.aa

-5.63

-0.19

-0.6

0.42

0.5

EBT, Excl. Unusual Items

aa.aa

160.69

299.62

1,065.45

-157.72

-62.05

Gain (Loss) On Sale Of Assets

aa.aa

0.31

-0.03

-0.36

1.93

5.67

Other Unusual Items, Total

aa.aa

0.78

14.51

-149.86

14.64

-33.38

EBT, Incl. Unusual Items

aa.aa

162.31

318.03

904.44

-153.24

-102.82

EBT, Incl. Unusual Items Growth

aa.aa

+28.5%

+95.94%

+184.39%

-116.94%

+32.91%

EBT, Incl. Unusual Items Margin

aa.aa

13.11%

17.88%

21.54%

-9.15%

-5.9%

Income Tax Expense

aa.aa

27.83

56.41

165.39

8.47

-4.23

Net Income to Company

aa.aa

134.48

261.62

739.06

-161.71

-98.59

Minority Interest

aa.aa

-24.1

-57.78

-121.73

20.12

-10.85

Net Income

aa.aa

110.38

203.84

617.32

-141.59

-109.44

Net Income Growth

aa.aa

+19.66%

+84.68%

+202.85%

-122.94%

+22.71%

Net Income Margin %

aa.aa

8.91%

11.46%

14.7%

-8.46%

-6.28%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

110.38

203.84

617.32

-141.59

-109.44

Basic EPS - Continuing Operations

aa.aa

0.31

0.58

1.54

-0.35

-0.27

Basic EPS - Continuing Operations Growth

aa.aa

+19.68%

+84.64%

+166.52%

-122.71%

+22.86%

Diluted EPS - Continuing Operations

aa.aa

0.31

0.58

1.54

-0.35

-0.27

Diluted EPS - Continuing Operations Growth

aa.aa

+19.68%

+84.64%

+166.52%

-122.71%

+22.86%

Basic Weighted Average Shares Outstanding

aa.aa

352.41

352.48

400.52

404.55

405.32

Diluted Weighted Average Shares Outstanding

aa.aa

352.41

352.48

400.52

404.55

405.32

Dividend Per Share

aa.aa

0.3

0.2

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

201.87

338.96

1,133.19

-106.34

-2.73

EBITDA Growth

aa.aa

+25.5%

+67.91%

+234.31%

-109.38%

+97.43%

EBITDA Margin %

aa.aa

16.3%

19.06%

26.99%

-6.35%

-0.16%

EBIT

aa.aa

158.18

294.15

1,070.98

-155.55

-62.37

* In Millions of CNY (except for per share items)

NSE 30

4,964.57

+32.18

+0.65%

NSE All Share

135,426.84

+973.91

+0.72%

US 30

44,925.00

+23.1

+0.05%

US 500

6,401.20

+12.6

+0.20%

FTSE 100

9,096.75

-23.56

-0.26%

DAX

24,171.81

-61.27

-0.25%

South Africa Top 40

91,399.97

+96.57

+0.11%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	28.40	+2.53%	14.14M
UBA	46.95	-0.11%	7.43M
Oando Plc	60.80	+1.25%	6.78M
MTN Nigeria	411.60	+2.90%	2.73M
Dangote Cement	497.90	+0.99%	1.65M
Geregu Power	1,027.40	-10.00%	1.00M
Okomu Oil Palm	1,025.00	+2.71%	745.90K

Name	Last	Chg. %	Vol.
Airtel Africa	2,541.50	+10.00%	18.00
Chellarams	11.00	+10.00%	10.24K
Champion Brew	13.55	+9.98%	2.56M
Tripple Gee and Co	3.70	+5.41%	494.76K
Guinness Nigeria	117.05	+9.96%	76.81K
UAC Of Nigeria	60.40	+9.92%	618.92K
UPDC REIT	9.45	+9.88%	2.53M

Name	Last	Chg. %	Vol.
Total Nig	634.50	-10.00%	14.50K
Geregu Power	1,027.40	-10.00%	1.00M
Abbey Mortgage Bank	7.20	-10.00%	96.20K
Transcorp Power	288.00	-10.00%	143.85K
Conoil	211.10	-9.98%	18.05K
Livingtrust Mortgage Bank	6.59	-9.97%	8.68K
Aluminum Ex	6.45	-9.79%	15.51K

Trending Stocks

Name	Last	Chg. %	Vol.
Champion Brew	13.55	+9.98%	2.56M
Initiates	16.30	+1.05%	4.89M
MTN Nigeria	413.00	+3.25%	2.68M
International Breweries	16.20	+6.58%	4.17M
UPDC REIT	9.45	+9.88%	2.53M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaa A Aaa	499.00	+31.13%	654.34
A A Aaaa Aaa Aaaa	5,200.00	+29.89%	6,754.28
Aa Aaa Aaaa A	69.85	+28.34%	89.65
Aaaa A	411.50	+10.34%	454.05

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Shanghai Labway Clinical Laboratory Co Ltd (301060)

301060 Income Statement

Trending Stocks